ANCA-associated vasculitis: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 200+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

No stopped trial with a stated reason in this view.

Trials whose registry record says individual participant data (IPD) will be shared.

• Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis

  NCT07160608· Alexion Pharmaceuticals, Inc.· Source

• Trial of VIS954 in the Treatment of Antineutrophil Cytoplasmic Antibody-associated Vasculitis

  NCT07904806· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source

• A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases

  NCT06512883· AstraZeneca· Source

• Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment

  NCT07444567· AstraZeneca· Source

• Iptacopan in Patients With ANCA Associated Vasculitis

  NCT06388941· Novartis Pharmaceuticals· Source

• Qualitative Study With Focus Groups of People Living With ANCA-associated Vasculitis (AAV) and Clinicians, to Explore Different Perspectives on Shared Decision-making in AAV.

  NCT07859995· University of the West of England· Source

• A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis

  NCT06072482· Amgen· Source

• CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis

  NCT07388277· Marcela V. Maus, M.D.,Ph.D.· Source

• Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA

  NCT06868290· Novartis Pharmaceuticals· Source

• ROSY-F: Roll-over Study for Participants Who Have Completed a Previous Clinical Study with Benralizumab (Fasenra) and Benefit from Continued Treatment

  2025-523307-29-00· AstraZeneca AB· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

See which targets of this disease your abstract mentions, and go to the people working on them.